I believe that the Neuren share price has mostly, for various...

I believe that the Neuren share price has mostly, for various reasons, been undervalued somewhere between 20-40% compared to its risk/reward profile ever since our initial contract with Acadia.

Potentially the major institutional investors are more risk averse than me and hence the profit available to the early retail investors willing to take greater risks.

The completion of all 4 trials for NNZ-2591, FDA approval for phase3, along with a further 9-12 months revenue from Daybue and approval in Canada should sufficiently reduce the perceived risks such that the share price should reflect closer to true value.

In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable.

It would surprise me if the board with their intimate knowledge of future potential could not see this type of scenario and value.